What medication can be used to treat antipsychotic‑induced rigidity and sialorrhea?

Management of Antipsychotic-Induced Rigidity and Sialorrhea

For antipsychotic-induced rigidity (parkinsonism), first attempt dose reduction or switch to another antipsychotic; if this fails or is not feasible, treat with an anticholinergic medication such as benztropine or trihexyphenidyl, though these should be avoided in elderly patients with dementia. 1, 2, 3

Antipsychotic-Induced Rigidity (Parkinsonism)

First-Line Management

• Dose reduction of the offending antipsychotic should be attempted first if clinically feasible 3
• Switch to another antipsychotic with lower extrapyramidal symptom (EPS) risk, particularly atypical agents like quetiapine or olanzapine 1, 4
• Atypical antipsychotics have diminished risk of developing extrapyramidal symptoms compared with typical agents 1

Pharmacological Treatment

• Anticholinergic medications are effective for treating drug-induced parkinsonism 2, 3
• The American Psychiatric Association recommends anticholinergic medication as a treatment option for antipsychotic-associated parkinsonism 3
• However, avoid benztropine (Cogentin) or trihexyphenidyl (Artane) in elderly patients, particularly those with Alzheimer's disease or dementia 1
• Amantadine (a mild dopaminergic agent) can also be used to treat parkinsonian symptoms 2

Important Caveats

• Differentiating between drug-induced parkinsonism and negative symptoms of schizophrenia (or catatonia in severe cases) can be difficult 2
• Children and adolescents may be at higher risk for extrapyramidal side effects than adults 2
• The need for antiparkinsonian agents should be reevaluated after the acute phase of treatment or if antipsychotic doses are lowered, as many patients no longer need them during long-term therapy 2

Antipsychotic-Induced Sialorrhea (Drooling)

Mechanism and Context

• Sialorrhea is most commonly associated with clozapine, though it can occur with other antipsychotics including risperidone, paliperidone, quetiapine, and aripiprazole 5, 6, 7, 8
• The pathophysiology varies between antipsychotics: clozapine-induced sialorrhea involves muscarinic mechanisms, while risperidone-induced sialorrhea likely has prominent adrenergic pathophysiology 7

Treatment Algorithm

Step 1: Non-Pharmacological Management

• Increase frequency of swallowing with chewing gum 8
• Patient education about the condition 8

Step 2: Dose Adjustment

• Reduce the dose of the causative antipsychotic if clinically feasible 8
• Split the daily dose to minimize peak effects 8

Step 3: Pharmacological Treatment

For clozapine-induced sialorrhea, the most effective agents based on network meta-analysis are (in descending order of efficacy) 6:

• Metoclopramide (most effective, RR=3.11)
• Cyproheptadine (RR=2.76)
• Sulpiride (RR=2.49)
• Propantheline (RR=2.39)
• Diphenhydramine (RR=2.32)
• Benzhexol/Trihexyphenidyl (RR=2.32) - effective at low doses (2 mg/day) 9
• Doxepin (RR=2.30)
• Amisulpride (RR=2.23)
• Chlorpheniramine (RR=2.20)
• Amitriptyline (RR=2.09)
• Atropine (RR=2.03, but not effective for nocturnal sialorrhea) 6

By mechanism of action, antimuscarinics, benzamides, tricyclic antidepressants, and antihistamines all significantly outperform placebo 6

For risperidone-induced sialorrhea 7:

• Dose reduction is more likely to be effective than with clozapine
• Alpha-2 adrenergic agonists (like clonidine) or beta-adrenergic antagonists are more likely to be effective
• Anticholinergic medications are less likely to be effective for risperidone-induced sialorrhea compared to clozapine-induced sialorrhea 7

Step 4: Alternative Interventions

• Benztropine can be used, though it was effective in treating paliperidone-associated sialorrhea in combination with atropine drops 5
• Glycopyrrolate and ipratropium did not outperform placebo in the network meta-analysis 6
• Botulinum toxin has been described as clinically effective in case reports 8

Monitoring Considerations

• Active interventions did not differ significantly from placebo regarding constipation or sleepiness/drowsiness 6
• Shared decision-making with the patient should guide treatment decisions 6
• The confidence in the evidence is low, prompting caution in interpretation 6